- Home
- BSM vs WGS Comparison
BSM vs WGS Comparison
Compare BSM & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- WGS
- Stock Information
- Founded
- BSM 1876
- WGS 2017
- Country
- BSM United States
- WGS United States
- Employees
- BSM N/A
- WGS N/A
- Industry
- BSM Oil & Gas Production
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- BSM Energy
- WGS Technology
- Exchange
- BSM Nasdaq
- WGS Nasdaq
- Market Cap
- BSM 2.6B
- WGS 2.4B
- IPO Year
- BSM 2015
- WGS N/A
- Fundamental
- Price
- BSM $11.97
- WGS $132.54
- Analyst Decision
- BSM Hold
- WGS Strong Buy
- Analyst Count
- BSM 1
- WGS 7
- Target Price
- BSM $13.00
- WGS $99.29
- AVG Volume (30 Days)
- BSM 503.2K
- WGS 666.9K
- Earning Date
- BSM 11-03-2025
- WGS 10-28-2025
- Dividend Yield
- BSM 10.03%
- WGS N/A
- EPS Growth
- BSM N/A
- WGS N/A
- EPS
- BSM 1.16
- WGS 0.05
- Revenue
- BSM $413,675,000.00
- WGS $362,321,000.00
- Revenue This Year
- BSM $10.58
- WGS $35.84
- Revenue Next Year
- BSM $14.68
- WGS $18.46
- P/E Ratio
- BSM $10.28
- WGS $2,732.19
- Revenue Growth
- BSM N/A
- WGS 48.70
- 52 Week Low
- BSM $11.90
- WGS $28.86
- 52 Week High
- BSM $15.66
- WGS $134.43
- Technical
- Relative Strength Index (RSI)
- BSM 39.85
- WGS 70.44
- Support Level
- BSM $11.97
- WGS $125.00
- Resistance Level
- BSM $12.24
- WGS $134.43
- Average True Range (ATR)
- BSM 0.19
- WGS 5.80
- MACD
- BSM 0.01
- WGS -0.57
- Stochastic Oscillator
- BSM 12.26
- WGS 90.63
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.